Longitudinal 3He Magnetic Resonance Imaging of Healthy Lung
1 other identifier
interventional
66
1 country
1
Brief Summary
Healthy elderly subjects male and female aged 65-85 will undergo MRI, lung function and exercise testing for the development of tools to quantify and validate longitudinal in vivo magnetic resonance imaging phenotypes of the aging lung.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable healthy
Started Sep 2010
Longer than P75 for not_applicable healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2010
CompletedFirst Submitted
Initial submission to the registry
June 24, 2015
CompletedFirst Posted
Study publicly available on registry
June 26, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2025
CompletedAugust 11, 2025
June 1, 2024
14.3 years
June 24, 2015
August 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ventilation Defect Percent (VDP)
Whole lung and segmental 3He MRI ventilation defect percent (VDP) are calculated by normalizing the volumes of 3He ventilation defects to the spatially matched CT whole lung and lung segments
3 years
Secondary Outcomes (1)
Apparent Diffusion Coefficients (ADC)
3 years
Study Arms (1)
Healthy Volunteers
OTHERHealthy elderly volunteers will undergo pulmonary function tests, hyperpolarized Helium-3 MRI at each visit.
Interventions
Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, Helium-3 gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
Eligibility Criteria
You may qualify if:
- Subjects male and female aged 60-90
- Subject has a smoking history of \< 0.5 pack years
- Subject understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent
- Subject must be able to perform a breathhold for 16s.
- BMI 18-30
- Subject is judged to be in stable health on the basis of medical history
- Subject able to perform reproducible pulmonary function testing (i.e., the 3 best acceptable spirograms have FEV1 values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater.)
You may not qualify if:
- Subject is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand the written material.
- Subject has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension (≥160 over ≥100)
- Subject has a daytime room air oxygen saturation \<90% while lying supine.
- Subject is unable to perform spirometry or plethysmography maneuvers
- Subject is unable or unwilling to ride a stationary bicycle
- Subject is pregnant
- In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia.
- Subject has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb,
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre
London, Ontario, N6A 5B7, Canada
Study Officials
- PRINCIPAL INVESTIGATOR
Grace E Parraga, PhD
Robarts Research Institute, The University of Western Ontario
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD, Scientist. Robarts Research Institute
Study Record Dates
First Submitted
June 24, 2015
First Posted
June 26, 2015
Study Start
September 1, 2010
Primary Completion
January 1, 2025
Study Completion
January 1, 2025
Last Updated
August 11, 2025
Record last verified: 2024-06